MAYN.F Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.00 |
| 52 Week High | AU$4.59 |
| 52 Week Low | AU$2.54 |
| Beta | 1.25 |
| 11 Month Change | -4.61% |
| 3 Month Change | n/a |
| 1 Year Change | -4.15% |
| 33 Year Change | -26.25% |
| 5 Year Change | -52.46% |
| Change since IPO | -67.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAYN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | -4.2% | 9.9% | 31.6% |
Return vs Industry: MAYN.F underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: MAYN.F underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| MAYN.F volatility | |
|---|---|
| MAYN.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MAYN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MAYN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| MAYN.F fundamental statistics | |
|---|---|
| Market cap | US$236.25m |
| Earnings (TTM) | -US$109.58m |
| Revenue (TTM) | US$252.40m |
0.9x
P/S Ratio-2.2x
P/E RatioIs MAYN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAYN.F income statement (TTM) | |
|---|---|
| Revenue | AU$388.40m |
| Cost of Revenue | AU$169.62m |
| Gross Profit | AU$218.78m |
| Other Expenses | AU$387.39m |
| Earnings | -AU$168.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 56.33% |
| Net Profit Margin | -43.41% |
| Debt/Equity Ratio | 7.0% |
How did MAYN.F perform over the long term?
See historical performance and comparison